



Correction to: Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis

Adham Fani Maleki¹ · Giulia Cisbani¹ · Nataly Laflamme¹ · Paul Prefontaine¹ · Marie-Michele Plante¹ · Joanie Baillargeon¹ · Manu Rangachari¹ · Jean Gosselin² · Serge Rivest¹

Published online: 27 April 2021

© The American Society for Experimental NeuroTherapeutics, Inc. 2021

<https://doi.org/10.1007/s13311-020-00998-0>

This article was corrected to add the captions to the supplementary figures.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s13311-020-00998-0>

✉ Serge Rivest
serge.rivest@crchudequebec.ulaval.ca

¹ Neuroscience Laboratory, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, 2705 Laurier Boul., Quebec City, QC G1V 4G2, Canada

² Laboratory of Innate Immunity, CHU of Quebec Research Center and Department of Molecular Medicine, Faculty of Medicine, Laval University, Laval University, 2705 Laurier Boul., Quebec City, QC G1V 4G2, Canada